Lucentis (ranibizumab) NDC 50242-082

NDC codes

FDA NDC Directory

Product NDC (as listed)50242-082Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50242-0082Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50242-082-03	50242008203	1 SYRINGE, GLASS in 1 CARTON (50242-082-03) / .05 mL in 1 SYRINGE, GLASSMarketed from Mar 20, 2018
50242-082-88	50242008288	1 SYRINGE, GLASS in 1 CARTON (50242-082-88) / .05 mL in 1 SYRINGE, GLASSMarketed from Mar 20, 2018 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lucentis
Generic name (nonproprietary): ranibizumab
Active ingredients: Ranibizumab — 6 mg/mL
Dosage form: Injection, Solution
Route: Intravitreal
Labeler: Genentech, Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125156
Marketing start: Aug 10, 2012
Listing expires: Dec 31, 2026
Other FDA classes: Vascular Endothelial Growth Factor Inhibitors (Mechanism)
Identifiers: Product ID 50242-082_71a6df7b-906b-4de9-ad4f-200285958cdcSPL ID 71a6df7b-906b-4de9-ad4f-200285958cdcSPL set ID de4e66cc-ca05-4dc9-8262-e00e9b41c36dRxCUI 1864423, 1864425, 2045501, 2045502UNII ZL1R02VT79
Pharmacologic class: Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J2778 — Injection, ranibizumab, 0.1 mg

Billing unit: 0.1 mg. Units on the claim = dose given ÷ 0.1 mg.

Ranibizumab biosimilars and the ranibizumab implant have their own HCPCS codes.

Administration

Intravitreal injection procedure (CPT 67028)

The intravitreal injection is reported as a separate procedure from the drug supplied.

How CPT relates to drug billing

NDC on a medical claim

N450242008203 followed by a unit qualifier and the quantity

Package 50242-0082-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 21, 2025.

Indications (excerpt from the label)

LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 125156

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 125156
Product	Strength	Form · route	Labeler	Product NDC
Lucentisranibizumab	Ranibizumab 10 mg/mL	Injection, SolutionIntravitreal	Genentech, Inc.	50242-080